Oncoguard® Liver
Use
The Oncoguard® Liver test is a novel approach aimed at the early-stage detection of hepatocellular carcinoma (HCC), the most common type of liver cancer. Early detection of HCC is crucial as it significantly improves outcomes, allowing curative treatments to be applied at a stage when they are more effective. The test utilizes a unique panel of DNA and protein markers selected for their sensitivity and specificity, providing reliable results that can empower treatment decisions and potentially increase long-term survival for patients at risk of HCC.
Special Instructions
The Oncoguard® Liver test is developed in collaboration with the Mayo Clinic and is supported by a Patient Engagement Program. This program includes educational materials, patient outreach, and reminders for regular testing, aiming to support adherence to a recommended surveillance schedule and empower patient involvement in their health management.
Limitations
While the Oncoguard® Liver test offers advanced sensitivity and specificity, it is important to be aware that no test can guarantee 100% accuracy. False positives and negatives can occur, and results should be interpreted by healthcare professionals in the context of the patient's overall clinical picture. The effectiveness of the test depends on the patient's adherence to regular surveillance schedules as recommended by healthcare providers.
Methodology
Other
Biomarkers
Result Turnaround Time
Not provided.
Related Documents
For more information, please review the documents below
Specimen
Whole Blood
Volume
Not provided
Minimum Volume
Not provided
Collection Instructions
The Oncoguard® Liver test is performed with a single blood draw, making the process straightforward and convenient for patients.